feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Living Drug Delivers Sci-Fi Cancer Cure in England

Living Drug Delivers Sci-Fi Cancer Cure in England

14 Jan

•

Summary

  • CAR T-cell therapy uses 100 million cells in a tiny dose.
  • The innovative treatment is developed in the UK for patients.
  • England offers this advanced therapy costing £372,000 per infusion.
Living Drug Delivers Sci-Fi Cancer Cure in England

A revolutionary CAR T-cell therapy, hailed as a landmark achievement in aggressive blood cancer treatment, is now accessible in England. This innovative 'living drug' involves infusing millions of the patient's own engineered T-cells, which then multiply and target cancer cells within the body. Oscar, one of the first patients, expressed amazement at the potent effectiveness of such a small, concentrated dose.

The CAR-T therapy was developed by Autolus, a UK-based spin-out from University College London, marking a significant advancement in domestic medical research. Previously, patients' cells required processing in US laboratories. The treatment's list price is £372,000 per infusion, though the NHS benefits from a confidential discount.

This therapy will be available to around 50 patients annually over the age of 26 with B-cell ALL that has proven resistant to other treatments. While initially offered in centers across England, patients from Wales and Northern Ireland will need to travel for treatment. Experts believe this therapy could eventually supersede stem cell transplantation as a first-line approach.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Oscar is receiving CAR T-cell therapy, a cutting-edge treatment where his own engineered T-cells are infused to fight his aggressive blood cancer.
The CAR T-cell therapy is available at several centers in England, including Cambridge, Newcastle, Sheffield, Plymouth, and London.
The list price for the CAR T-cell therapy is £372,000 per infusion, with the NHS having a confidential discount.

Read more news on

Healthside-arrowNorthern Irelandside-arrowEnglandside-arrow
trending

Winter storm closes schools

trending

Verizon offers outage credit

trending

California hit by earthquake

trending

China bans Broadcom cybersecurity

trending

New RFK Stadium renderings

trending

USAF jet causes sonic boom

trending

McConaughey protects image, voice

trending

SpaceX launch turnaround record

trending

Monks walk for peace

You may also like

King Charles' Cancer Fight: Precautionary Treatment Ahead

13 Dec, 2025 • 176 reads

article image

Teen's Cancer Vanquished by Gene-Edited Immune Cells

9 Dec, 2025 • 86 reads

article image

CHOP's CAR T Therapy Saves Young Lives

5 Dec, 2025 • 176 reads

article image

NHS Failing Prostate Cancer Patients: Focal Therapy Denied

30 Nov, 2025 • 212 reads

article image

Leukaemia Cure: NHS Approves Groundbreaking Cell Therapy

25 Nov, 2025 • 244 reads

article image